Aktie A2PYWE ARCUTIS BIOTHERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Arcutis Biotherapeutics, Inc.

Aktien

A2PYWE

US03969K1088

ARQT

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 24.06.2024 		% 5 Tage % 1. Jan.
8,88 USD +4,59 % Intraday Chart für Arcutis Biotherapeutics, Inc. +11,56 % +174,92 %
12.06. Transcript : Arcutis Biotherapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM
11.06. Sektor-Update: Gesundheitstitel am Dienstag vorbörslich uneinheitlich MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Arcutis Biotherapeutics Says Experimental Cream Showed Improvements in Atopic Dermatitis Symptoms
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Arcutis Biotherapeutics, Inc. Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (Ad) in Adults and Children Down to Age Six Presented At Revolutionizing Alopecia Areata, and Eczema Conference
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday
Sector Update: Health Care
Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket
Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q1 Revenue $49.6M
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PYWE Aktie
  4. Nachrichten Arcutis Biotherapeutics, Inc.
  5. Andere Sprachen